IPO Journey
Kailera Therapeutics, Inc.
IPO Date: April 17, 2026 · 3 filings tracked
Final Offer Terms
Ticker
KLRA
Exchange
Nasdaq Global Select Market
Offer Price
$16.00
Shares Offered
39,062,500
Estimated Proceeds
$625.0M
Underwriters
Led by J.P. Morgan, Jefferies
Leerink PartnersTD CowenEvercore ISIWilliam Blair
Filing Timeline
1
S-1
March 27, 2026
- Lead candidate ribupatide is currently in Phase 3 clinical trials
- Strategic partnership with Hengrui provides access to established drug research
2
S-1/A
April 13, 2026
- Developing a diversified pipeline of obesity and metabolic disease treatments
- Strategic partnership with Hengrui provides access to existing clinical data
Changes from previous filing
- ▸ Expected offer range: $14.0 – $16.0 per share
- ▸ Shares offered: 33,333,334
- ▸ Estimated proceeds: $466M
424B4
Final Pricing
April 17, 2026
- Targeting the high-growth obesity and metabolic disease market
- Leadership team with proven experience from Eli Lilly, Amgen, and Merck
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $16.0 per share
- ▸ Shares offered: 39,062,500
- ▸ Estimated proceeds: $625M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.